Current Atherosclerosis Reports

Papers
(The TQCC of Current Atherosclerosis Reports is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Revascularization Options for Left Main Disease: What Clinicians Need to Know151
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions136
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management113
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?110
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes93
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis76
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment76
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management75
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease69
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?66
The Role of the PI3K/Akt/mTOR Pathway in Atherosclerosis: Mechanisms, Therapeutic Potential, and Emerging Targeted Treatments65
The Effects of FABP4 on Cardiovascular Disease in the Aging Population64
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice61
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart57
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women53
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond50
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators49
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event42
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis41
Inflammation in the Peri-ACS Period: Ready for Prime Time?40
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?40
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?38
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?38
The Emerging Specialty of Cardio-Rheumatology37
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review36
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease35
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention33
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease33
Percutaneous Coronary Interventions in Women31
Myeloid Cells in Abdominal Aortic Aneurysm31
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women31
Lipoprotein(a): from Causality to Treatment30
Low LDL-C: Is It all Good News?29
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease29
The Role of Sleep in Cardiovascular Disease29
Importance of Nutrition Security to CVD Prevention Efforts in the USA29
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger28
Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations: What Clinicians Need to Know?28
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis27
Can Clinical Biomarkers Guide Optimal Therapeutic Selection in Type 2 Diabetes Mellitus? A Scoping Review27
Transgender Cardiovascular Health: Practical Management for the Clinician26
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know26
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?25
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment24
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis24
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion24
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?23
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference23
Exploring the Role of SPARC in Atherosclerosis: Mechanisms and Potential Implications23
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity22
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?22
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease22
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?22
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference21
Transforming Population Health Screening for Atherosclerotic Cardiovascular Disease with AI-Enhanced ECG Analytics: Opportunities and Challenges21
Factors Affecting Circulating Phytosterol Levels: Toward an Integrated Understanding of Atherogenicity and Atheroprotection by Dietary and Circulating Phytosterols21
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction20
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine20
Is There a Role for Imaging Youth at Risk of Atherosclerosis?20
Cardiovascular Disease in the Middle East and North Africa, 1990–2021: Burden, Trends, and Risk Factors19
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know19
HIV and Cardiovascular Disease Burden in Young Adults (18–25 years): A Review of Current Evidence19
Clinical Management of Dyslipidemia in Infants and Toddlers19
Gene Regulatory Networks in Coronary Artery Disease19
Cardiovascular Health and Disease in the Pakistani American Population18
Expanding Clinical Indications for Cardiac CT: A Review of Its Current Utility in American and European Guidelines18
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field17
Targeting the Gut Microbiome to Treat Cardiometabolic Disease17
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population17
What Causes Premature Coronary Artery Disease?17
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men16
High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review16
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference16
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults16
Bempedoic Acid: for Whom and When16
Natural Sirtuin1 Activators and Atherosclerosis: an Overview16
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician16
Dietary Management of Atherogenic Dyslipidemia15
Serial Coronary CTA for Monitoring Response to Lipid-Lowering Therapy: A Narrative Review15
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms14
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments14
Fixed Combination for the Treatment of Dyslipidaemia14
Utility of FFRCT in Patients with Chest Pain14
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach14
Circular RNA role in Atherosclerosis Development and Progression14
The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?14
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned14
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk14
0.068269968032837